Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAM9-MSN
- Development stage
- Preclinical
- Lead developer
- Vrije University Medical Center
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**ADAM9-MSN** is a preclinical, pancreatic ductal adenocarcinoma-targeted mesoporous silica nanoparticle drug-delivery platform. It uses an avidin-biotin gatekeeper system with an ADAM metallopeptidase domain 9-cleavable peptide linker, intended to release encapsulated chemotherapy preferentially in ADAM9-enriched pancreatic tumor microenvironments. Paclitaxel-loaded ADAM9-MSNs were cytotoxic to pancreatic cancer cells in vitro, but later preclinical studies found off-target toxicity and no meaningful in vivo antitumor response despite optimized formulations, prompting development of intracellular-protease-responsive alternatives. ([mdpi.com](https://www.mdpi.com/2072-6694/13/13/3321))
- Other names
- ADAM9-MSNsADAM-9-MSNsADAM 9-MSNsADAM9-responsive mesoporous silica nanoparticleADAM-9-responsive mesoporous silica nanoparticleADAM 9-responsive mesoporous silica nanoparticleADAM9-responsive mesoporous silica nanoparticlesADAM-9-responsive mesoporous silica nanoparticlesADAM 9-responsive mesoporous silica nanoparticles
02
Targets
TUBB (Tubulin (alpha and beta subunits))ADAM9
Beyond the preview
Go deeper on ADAM9-MSN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAM9-MSN.